| Document |
Document Title |
|
WO/2010/038167A1 |
The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of Formula (I) : as defined in the specification. The invention is also directed to compositions co...
|
|
WO/2010/032988A2 |
The present invention relates to a kojic acid metal complex derivative bonded with an amino acid. More specifically, the invention relates to a kojic acid metal complex derivative into which an amino acid is introduced, and a preparation...
|
|
WO/2010/031813A1 |
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts, to formulations and uses in the treatment of, interalia, metabolic disorders.
|
|
WO/2010/031820A1 |
The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts, to formulations and uses in the treatment of metabolic disorders.
|
|
WO/2010/031750A1 |
The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
|
|
WO/2009/124723A9 |
This invention relates to the field of biologically active compounds and specifically to novel aureothin derivatives, pharmaceutical compositions comprising these novel aureothin derivatives, methods for the production of the aureothin d...
|
|
WO/2010/030395A2 |
The present invention provides a novel class of withanolides that have been isolated from W. somnifera under aeroponic conditions or produced semi-synthetically from withanolide natural products. The invention also provides pharmaceutica...
|
|
WO/2010/027418A1 |
Described herein are C5-C6 annelated naphthopyrans that possess at least one electron-withdrawing group. The compounds possess desirable properties such as increased fading kinetics. Also described herein are new methods for synthesizing...
|
|
WO/2010/022313A2 |
Provided are processes for the preparation of complexes that are useful in purifying compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The processes can reduce the number of steps needed to obtain the ...
|
|
WO/2010/010578A2 |
The present invention provides a scalable process for the preparation of Stilbenes by (i) condensing 3,5-dialkylbenzyl phosphonates with 4'-O-tetrahydropyranyl benzaldehyde to get 3,5-alkyl-4'-O-tetrahydropyranyl Stilbene (ii) deprotecti...
|
|
WO/2010/007027A1 |
The present invention provides a compound of formula (I) said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP- 13....
|
|
WO/2010/001821A1 |
Disclosed are a compound represented by general formula (I) (wherein R1 and R2 each represents a hydrogen, a lower acyl, a lower alkoxycarbonyl or the like; R3 represents a lower alkyl, a halogenated lower alkyl, a cycloalkyl, a heterocy...
|
|
WO/2010/000773A1 |
Compounds of formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.
|
|
WO/2009/156889A1 |
The invention relates to derivatives of a compound of formula I: wherein R1 to R7 and X1 to X7 are as defined herein The invention relates to the uses thereof for treating diseases, conditions and/or disorders mediated by kappa opioid re...
|
|
WO/2009/158381A1 |
The present invention provides compounds according to Formula (I): or pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, and isomers thereof, wherein: ring A, n, q, R1, R2, R3, R4, R5, R6, each R7, each R7A, and R8...
|
|
WO/2009/157313A1 |
Disclosed is a liquid crystalline compound having excellent properties including highly negative dielectric anisotropy. Also disclosed is a liquid crystal composition which comprises the compound. Further disclosed is a liquid crystal ...
|
|
WO/2009/154766A1 |
Disclosed are aspartic protease inhibitors represented by the following Formula: wherein R1 , R2, R3, R4, R5, R6, R7a, R7b and n are as defined herein, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising...
|
|
WO/2009/150094A1 |
Pyranone, thiopyranone and cyclohexenedione compounds of formula (I), which are suitable for use as herbicides.
|
|
WO/2009/150095A1 |
Pesticidal compositions containing pyrandione, thiopyrandione and cyclohexanetrione compounds and methods of using them to combat and control pests such as insect, acarine, mollusc and nematode pests.
|
|
WO/2009/150093A1 |
Pyrandione, thiopyrandione and cyclohexanetrione derivatives of formula (I), which are suitable for use as herbicides.
|
|
WO/2009/148282A2 |
The present invention relates to a diaryl hepatonoid compound of chemical formula (1) having virus inhibitory activity; its pharmaceutically acceptable salts; its hydrates, solvates or prodrugs; and a pharmaceutical composition containin...
|
|
WO/2009/139438A1 |
Disclosed is a process for producing an optically active carboxylic acid from a racemic carboxylic acid in a conventional production facility with high efficiency and at low cost. Specifically disclosed is a process for producing an opt...
|
|
WO/2009/136534A1 |
Disclosed is a liquid crystalline compound having excellent characteristics such as large negative dielectric anisotropy. A liquid crystal composition using the compound and a liquid crystal display device are also disclosed. A compound ...
|
|
WO/2009/132453A1 |
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and/or T-type calcium channel activity are disclosed. Specifically, a series of compounds of subs...
|
|
WO/2009/131246A1 |
This invention relates to a new sordarin derivative or a pharmaceutically acceptable salt thereof, which has antimicrobial activities (especially, antifungal activities), to process for preparation thereof, to a pharmaceutical compositio...
|
|
WO/2009/129726A1 |
The present invention provides novel nitrones, their preparation and use. The novel compounds have the following formula: I The compounds of the present invention have strong antioxidative activity, and are thrombolytic. These compounds ...
|
|
WO/2009/130192A1 |
A process of preparing a compound of formula (I) wherein R represents a linear or branched C5 alkyl group, as well as the use of such compounds in a fragrant and/or flavouring composition.
|
|
WO/2009/124638A1 |
Disclosed are novel compounds of formula (I) in which X has the meaning indicated in claim 1. Said compounds are suitable as antidiabetics.
|
|
WO/2009/121939A2 |
This invention relates to a compound of generic formula (I): (I) as well as a pharmaceutically acceptable salt thereof, a tautomer, optical isomer or a mixture of optical isomers in any proportion, in particular a mixture of enantiomers,...
|
|
WO/2009/121245A1 |
Novel Fostriecin (or FST) derivatives represented by formula (I), the pharmaceutical compositions and preparation methods thereof. The pharmaceutical uses of these compounds, especially the use for the preparation of pharmaceutical compo...
|
|
WO/2009/118168A1 |
The invention relates to compounds which have an affinity to the ยต-opioid receptor and ORL1 receptor, to processes for preparation thereof, to medicaments comprising these compounds and to the use of these compounds for producing medica...
|
|
WO/2009/118538A2 |
The present invention relates to a novel carbohydrate lactone, functionalized aliphatic polyesters and copolymers formed therefrom, and processes for the preparation thereof from renewable resources.
|
|
WO/2009/116657A1 |
A method for producing cycloalkanedicarboxylic acid monoester including, (A) a process for obtaining a compound represented by formula (2) by protecting any one of two compounds of carboxyl groups represented by formula (1) with a group ...
|
|
WO/2009/110003A1 |
The present invention provides a flavonol compound and a bioactive extract/fraction from Ulmus wallichiana useful for the management or prevention or treatment of bone disorders. Said extract/fraction comprising marker compounds of gener...
|
|
WO/2009/108272A1 |
Skin brightening compositions based on esters of 5-hydroxy-2-methyl-4H- pyran-4-one. Also disclosed are methods of making the compositions as well as methods of using the compositions.
|
|
WO/2009/106552A2 |
The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds ...
|
|
WO/2009/104849A1 |
Disclosed are cis-2,6-disubstituted tetrahydropyran derivatives and a preparation method thereof. The tetrahydropyran derivatives can be prepared by Prins-reacting tetrahydropyran derivatives with homopargylicalcohol derivatives in the p...
|
|
WO/2009/096455A1 |
Disclosed is a pharmaceutical composition which is useful as a therapeutic agent for fatty liver diseases. The pharmaceutical composition comprises (1S)-1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-hydroxyphenyl]-D
-glucitol or a pharmaceutica...
|
|
WO/2009/092702A2 |
The present invention relates to ((2S,4R)-4,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl carboxylates and a process for the production thereof. Furthermore, the present invention relates to a process for the production of statins and in pa...
|
|
WO/2009/089210A1 |
The present invention is directed to novel processes for the preparation of sulfamide derivatves, useful in the treatment of epilepsy and related disorders.
|
|
WO/2009/080761A1 |
A compound of general formula (I) wherein A, Y, W, R1, R2, R3, R4, R5, and R6 take various meanings for use in the treatment of cancer.
|
|
WO/2009/081892A1 |
Disclosed is a compound represented by the general formula (I) below which has a strong COMT inhibitory effect, or a pharmacologically acceptable salt thereof. Also disclosed are a pharmaceutical composition containing such a compound or...
|
|
WO/2009/077186A1 |
The present invention relates to nonsteriodal progesterone receptor modulators of the general formula 1, the use of the progesterone receptor modulators for producing medicaments and also pharmaceutical compositions containing these comp...
|
|
WO/2009/077677A2 |
The invention relates to novel polyspirane compounds used in the treatment of diseases involving parasites that belong to the phylum of apicomplexae, and to a method for preparing the same.
|
|
WO/2009/078033A2 |
The present invention relates to a novel process for isolation and recovery of compounds such as biosynthetically produced simvastatin in either lactone form or in the form of its acid salt in high yield and purity, from microbial fermen...
|
|
WO/2009/077550A1 |
The present invention relates to a method for producing cis-2-(2-methyl-prop-1-ene-yl)-4-methyl-tetrahydropyrane, comprising the catalytic hydration of 2-(2-methyl-prop-1-ene-yl)-4-methylene-tetrahydropyrane in the presence of hydrogen a...
|
|
WO/2009/074314A1 |
Pyrandione, thiopyrandione and cyclohexanetrione compounds, which are suitable for use as herbicides.
|
|
WO/2009/069589A1 |
Disclosed is 1-(2-(4-((2,3-dihydro(1,4)dioxino(2,3-c)pyridin-7-ylmethyl)a
mino)piperidin-1-yl)ethyl)-7-fluoro-1,5-naphthyridin-2(1H)-o
ne monohydrate, which has a strong antibacterial activity. The compound is highly safe and useful as a...
|
|
WO/2009/064418A1 |
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In...
|
|
WO/2009/059996A1 |
This invention relates to a synthetic nutritional composition suitable for use in the prevention of secondary infections following a viral infection characterised by neuraminidase activitycomprising a sialylated oligosaccharide and N-ace...
|
